Yik Wo International (08659) announces financial performance for 2025. The attributable loss for the year is expected to be approximately 6.773 million yuan, a year-on-year change from profit to loss.

YIK WO INTL (08659) announced its performance for the year 2025, with revenue of approximately 178 million yuan, a year-on-year decrease of about 42.5%. The company's attributable loss for the year is estimated to be about 6.773 million yuan, turning from profit to loss compared to the previous year. The announcement stated that the increase in net loss was mainly due to a large number of the group's products being included in the "National Centralized Procurement" plan launched by the government of the People's Republic of China in 2025. National Centralized Procurement is a key national policy implemented to lower drug prices and reduce the burden of public medical expenses. In accordance with the pricing mechanism of this national policy, the group has adjusted the selling prices of relevant procurement products, resulting in a significant narrowing of the gross profit margin of the affected products, thereby adversely affecting the overall profitability of the group in the current year.